|Code No.||PM098||Print out|
|Availability (in Japan)||10 or more
（In Japan at 17:00, Aug 9, 2022 in JST）
|Rabbit Ig (aff.)|
|Applications||IP 10 µL/sample
IH** Can be used.
ELISA Can be used.
DB Can be used.
|Carrier protein-conjugated Inosine|
|Storage buffer||PBS/50% glycerol, pH 7.2|
|Alternative names||Ino, I|
|Background||Adenosine-to-inosine (A-to-I) RNA editing, the most common modification that occurs in mammalian mRNAs and ncRNAs, is the conversion of adenosine to inosine catalyzed by members of the adenosine deaminase acting on RNA (ADAR) family. Because inosine has a similar chemical structure to guanosine, it pairs preferentially with cytidine. This influences the regulation of splicing, stabilization, and translation. A-to-I RNA editing also affects miRNA biogenesis and their recognition by target mRNAs. A malfunction in the editing mechanism results in various human diseases such as neurological disorders and cancers.|
|Related products||D347-3 Anti-Pseudouridine mAb
D345-3 Anti-1-methyladenosine (m1A) mAb
D346-3 Anti-5-methylcytidine (m5C) mAb
PM077 Anti-5-hydroxymethylcytosine (5hmC) pAb
MI-11-3 Anti-Bromodeoxyuridine mAb
MI-11-5 Anti-Bromodeoxyuridine mAb-PE
M218-3 Anti-5-hydroxymethylcytosine (5hmC) mAb
RN019M Anti-2,2,7-trimethylguanosine (m3G/TMG) mAb
RN016M Anti-7-methylguanosine (m7G)-Cap mAb
RN017M Anti-7-methylguanosine (m7G) mAb
|Product category||Research area:RNA-RNP Network Epigenetics|